Idelalisib Is Not Associated With Increased Bleeding Risk in Patients With Relapsed Chronic Lymphocytic Leukemia and Indolent Non–Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
No Increased Bleeding Events in Patients With Relapsed Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Treated With Idelalisib
Leukemia and Lymphoma 2020 Dec 10;[EPub Ahead of Print], JC Barrientos, P Hillmen, G Salles, J Sharman, S Stilgenbauer, O Gurtovaya, G Xing, B Ruzicka, P Bhargava, P Ghia, JM PagelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.